Summary: Therapeutic advances in breast cancer;Mammakarzinom - Therapeutische fortschritte

Therapeutische Umschau

Volumn 63, Issue 4, 2006, Pages 255-261

  Pestalozzi, B C ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; HUMAN; MONOTHERAPY; PROTEIN EXPRESSION; REVIEW; SENTINEL LYMPH NODE BIOPSY;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; RNA, MESSENGER; RNA, NEOPLASM; SENTINEL LYMPH NODE BIOPSY; TIME FACTORS;

EID: 33646018039     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.63.4.255     Document Type: Review

References (8)

1. th ed. New York: Wiley-Liss, 2002; 131-41.
2. th ed. New York: Springer 2002; 223-40.)
3. Harlow SP, Weaver DL. Management of the regional lymph nodes in breast cancer. www.uptodateonline.com (April 2005).
4. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353: 1652-54.
5. Sauter G, Simon R. Predictive molecular pathology. N Engl J Med 2002; 347: 1995-96.
6. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431-42.
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic brest cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
8. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-83.